NEXIUM Drug Patent Profile

Which patents cover Nexium, and what generic alternatives are available?

Nexium is a drug marketed by Astrazeneca and Astrazeneca Lp and is included in six NDAs.

The generic ingredient in NEXIUM is esomeprazole sodium. There are seventy-four drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the esomeprazole sodium profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Nexium

A generic version of NEXIUM was approved as esomeprazole sodium by DEVA HOLDING AS on March 6^th, 2017.

Summary for NEXIUM

US Patents:	0
Applicants:	2
NDAs:	6
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for NEXIUM

Paragraph IV (Patent) Challenges for NEXIUM

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
NEXIUM	Delayed-release for Oral Suspension	esomeprazole magnesium	2.5 mg and 5 mg	021957	1	2018-09-24
NEXIUM	Delayed-release for Oral Suspension	esomeprazole magnesium	10 mg	022101	1	2018-07-06
NEXIUM	Delayed-release for Oral Suspension	esomeprazole magnesium	20 mg and 40 mg	021957	1	2013-08-01
NEXIUM	Delayed-release Capsules	esomeprazole magnesium	20 mg and 40 mg	021153	1	2005-08-05

US Patents and Regulatory Information for NEXIUM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astrazeneca	NEXIUM	esomeprazole magnesium	CAPSULE, DELAYED REL PELLETS;ORAL	021153-001	Feb 20, 2001	AB	RX	Yes	No
Astrazeneca	NEXIUM	esomeprazole magnesium	FOR SUSPENSION, DELAYED RELEASE;ORAL	021957-002	Oct 20, 2006	AB	RX	Yes	Yes
Astrazeneca	NEXIUM	esomeprazole magnesium	FOR SUSPENSION, DELAYED RELEASE;ORAL	021957-004	Dec 15, 2011	AB	RX	Yes	No
Astrazeneca Lp	NEXIUM 24HR	esomeprazole magnesium	CAPSULE, DELAYED RELEASE;ORAL	204655-001	Mar 28, 2014		OTC	Yes	Yes

International Patents for NEXIUM

See the table below for patents covering NEXIUM around the world.

Country	Patent Number	Title	Estimated Expiration
Denmark	420982
Finland	90393
Norway	2011010
European Patent Office	0171372	SULPHENAMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE IN THE MANUFACTURE OF PHARMACEUTICAL PREPARATIONS

Supplementary Protection Certificates for NEXIUM

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0005129	SPC/GB99/015	United Kingdom		SPC/GB99/015, EXPIRES: 20021115
0984957	CR 2012 00035	Denmark		PRODUCT NAME: ET KOMBINATIONSPRODUKT AF NAPROXEN OG ESOMEPRAZOL MAGNESIUM TRIHYDRAT; NAT. REG. NO/DATE: 49583 20120327; FIRST REG. NO/DATE: GB PL 17901/0263-001 20101105
1411900	2011C/016	Belgium		PRODUCT NAME: NAPROXENE ET ESOMEPRAZOLE (SOUS LA FORME D'ESOMEPRAZOLE MAGNESIUM TRIHYDRATE); AUTHORISATION NUMBER AND DATE: BE382505 20101214
0984957	91871	Luxembourg		91871, EXPIRES: 20230525

NEXIUM (esomeprazole): Investment Scenario and Fundamentals Analysis

Last updated: April 25, 2026

What is Nexium and where does it sit in the drug portfolio?

Nexium is the brand name for esomeprazole, a proton-pump inhibitor (PPI). It is used for acid-related gastrointestinal conditions, including GERD and erosive esophagitis, and it is also used in Helicobacter pylori eradication regimens and in acid suppression for conditions such as Zollinger-Ellison syndrome (US labeling). Nexium is a legacy, largely patent-expired asset in most major markets, with the competitive set dominated by generic esomeprazole and other PPIs.

Core commercial reality: Nexium is not a “pipeline-like” IP story. It is a brand-and-formulation value story operating in a mature class.

---

How does the patent and IP position shape the investment case?

Most jurisdictions moved to generic competition for esomeprazole years ago, making the enduring value of Nexium dependent on:

• Brand retention (prescriber familiarity, patient switching frictions)
• Packaging, dosing formats, and adherence support (where brand value is defended)
• Regional payor dynamics (formulary placement versus generic default)
• Indication mix and clinical positioning (e.g., alignment with guideline use patterns)

Investment implication: the “fundamental driver” is no longer exclusivity. It is share stability and margin protection in the face of generic pricing pressure.

---

What is the competitive landscape for Nexium?

Nexium competes in two layers:

Within-class competition (PPIs)

Common alternatives include other PPIs (e.g., omeprazole, lansoprazole, pantoprazole, rabeprazole, dexlansoprazole). Class competition matters because payors often treat PPIs as therapeutically substitutable and encourage lower-cost options.

Generic esomeprazole competition

Once generics are available, Nexium’s economics shift from exclusivity to:

• Price premium capture where formularies allow brand access
• Reimbursement structure (copays, step therapy policies)
• State-level and PBM-led contracting outcomes

Investment implication: the base-case valuation for Nexium-linked exposure typically uses an assumption of continued generic penetration and declining brand share over time, offset by any brand-for-life contracting strategies and mix effects.

---

What do the fundamentals say about market demand and durability?

PPIs are high-volume chronic-use medicines. Demand is durable because indications map to common GI diagnoses and guideline-directed long-term acid suppression occurs in subsets of patients.

Key durability factors:

• Steady prevalence of GERD and dyspepsia-related presentations
• Ongoing guideline adoption for initial therapy and maintenance in appropriate patients
• Broad distribution and clinician familiarity

Key erosion factors:

• Persistent generic substitution
• Formulary tiering and step edits
• Long-run class price compression

Investment implication: Nexium’s “durability” is real but the revenue trajectory is structurally downward from generic competition unless brand access is actively defended.

---

What is the demand funnel: key indications and how they affect revenue?

Nexium’s sales profile typically tracks payor coverage across:

• GERD and erosive esophagitis treatment
• Maintenance therapy in selected populations
• H. pylori eradication regimens (in combination products)
• Chronic acid suppression conditions such as Zollinger-Ellison

Revenue mechanism: Even in a generic world, brand demand can persist when prescribers keep patients on a familiar regimen, and where formulary restrictions do not fully eliminate brand access.

---

What is the cost and margin structure versus generics?

In generic competition, brand economics usually compress due to:

• Lower realized price as payer pressure intensifies
• Higher promotional intensity needed to defend share
• Higher cost-to-serve relative to generic supply chains

What tends to protect a portion of margin is:

• Contracted access that reduces the degree of substitution
• Patient adherence and lower switching
• Formulation advantage in specific dosing routes or regimen preference (where applicable)

Investment implication: any investment case tied to Nexium must treat margin as a dependent variable to formulary status, not as a stable constant.

---

How does regulatory and safety positioning influence prescribing behavior?

PPIs face periodic label updates and ongoing safety monitoring, but esomeprazole remains an established option. For brand demand, the critical factor is not new efficacy claims but clinical comfort and reassurance stability within established label frameworks.

Investment implication: regulators rarely remove PPIs from standard of care; instead, market behavior shifts through reimbursement and payor controls. That favors predictability but limits upside.

---

What are the key investment scenarios for Nexium exposure?

Because Nexium is mature, the investment framework is scenario-driven around share, pricing, and contracting.

Scenario 1: Base case (generic gravity)

• Continued generic substitution
• Gradual brand share decline
• Margin compression follows realized price decline

Outcome: returns align with a slow erosion profile, with limited upside catalysts.

Scenario 2: Contracting resilience (brand holds share)

• Stronger-than-expected formulary access
• Higher than assumed brand conversion and lower switching off-brand
• Mix improvement via favored dosing formats or institutional retention

Outcome: slower decline than base-case, modestly better margins.

Scenario 3: Acceleration (formulary downgrade / step therapy expansion)

• Stronger PBM restrictions and step edits
• Increased use of the lowest-cost generic PPI
• Brand access narrowed in priority plans

Outcome: faster revenue and margin compression; valuation downside risk increases.

---

How should investors underwrite a Nexium-linked valuation (practical checkpoints)?

Underwriting should be built around metrics that actually drive net revenue in a generic market:

1. Formulary tiering

   • Whether Nexium remains on preferred tiers or is moved to non-preferred tiers

2. PBM rules

   • Step edits and prior authorization patterns for PPIs

3. Share versus the generic esomeprazole basket

   • Brand share trend relative to generic penetration in target geographies

4. Net price and discounting

   • Realized prices after rebates and payer contracting

5. Switching dynamics

   • Rates at which patients and prescribers move to other PPIs or lower-cost generics

Investment implication: these checkpoints matter more than brand-level efficacy narratives.

---

What is the “fundamentals scorecard” for Nexium?

Category	Fundamentals direction	Investment relevance
Indication demand	Durable	Supports baseline volume
Class competition	High	Caps pricing power
Generic substitution	Ongoing	Drives long-run revenue erosion
Brand access	Contract-driven	Key determinant of net price and share
Margin	Compressing in downtrend	Dependent on net price vs promotional intensity
Catalysts	Limited for mature drug	Upside requires contracting resilience or mix shifts

---

Where are the main risks?

The dominant risks are market structure risks:

• Payer policy tightening (tiering, step therapy)
• Generic price falls impacting the brand’s net price gap
• Share dilution to other PPIs if rebates and plan preferences shift
• Volume decline if prescriber behavior changes due to guideline interpretation or utilization management

There are also operational and legal risks for established products, but for a Nexium thesis the primary return drivers are reimbursement and contracting, not new clinical entrants.

---

Key Takeaways

• Nexium is a mature PPI brand (esomeprazole) with value driven by brand access, formulary placement, and net price, not by patent exclusivity.
• Generic esomeprazole and within-class PPIs dominate competition, creating structurally downward pricing and share pressure.
• The investable upside in a Nexium exposure case comes from contracting resilience (slower than expected brand share decline) rather than from clinical or regulatory step-changes.
• Underwriting should focus on payer and PBM mechanics, realized net price, and brand share vs the generic basket.

---

FAQs

1) Is Nexium still protected by meaningful exclusivity?

Nexium’s core value is not driven by current exclusivity in most markets; it operates in a generics-dominant environment, making reimbursement and contracting the primary levers.

2) What most influences Nexium revenue after generic entry?

The biggest drivers are formulary tiering, PBM step edits, realized net price after rebates, and brand share stability versus generic esomeprazole and other PPIs.

3) What clinical areas sustain Nexium demand?

GERD-related indications, maintenance in appropriate patients, and use in H. pylori regimens and other chronic acid suppression scenarios.

4) How should an investor model price versus volume?

Model both: brand volume typically declines with substitution, while net price compresses faster when tiering worsens or payer rebates change.

5) Where can upside come from in a mature PPI brand?

From stronger-than-expected brand access and reduced switching due to contracting, plan-specific preferences, and mix effects tied to dosing format and institutional retention.

---

References

[1] U.S. Food and Drug Administration. (n.d.). Nexium (esomeprazole magnesium) prescribing information. FDA. https://www.accessdata.fda.gov/